Key Drivers
- Strong Liquidity
- No Revenue
- Rich Valuation
AIAI Summary
SYRE has shifted from a survival-funding story to a high-upside, high-valuation clinical execution bet: with $1.2B cash and positive SKYLINE UC data, the stock now hinges on replicating efficacy across the 2026 readout calendar, where any miss could sharply reset sentiment after the recent rerating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •No Revenue
- •Rich Valuation
SYRE has excellent liquidity and no debt, but persistent no-revenue cash burn, widening quarterly losses, and a 9.19x price-to-book make the stock look financially safe near term yet expensive and risky longer term.
Price Behavior
Key Price Behavior Insights:
- •Rebound intact
- •Resistance cap
- •Momentum cooling
Over the last month, SYRE rebounded sharply from a late-April low near $68.63, but is now consolidating under $76.3-$76.4 resistance while holding above $73 support.
Sharp rebound from $68.63 to the $76.31-$76.43 area, then a pullback into consolidation
Sentiment & News
Key News Insights:
- •Phase 2 momentum
- •Strong cash runway
- •Accelerated readouts
Spyre Therapeutics (SYRE) posted encouraging Phase 2 efficacy and safety data, accelerated multiple readouts, and boosted its balance sheet with a $463M raise, supporting a longer cash runway into 2029.
The positive clinical signal plus ample funding and a packed catalyst calendar should remain supportive for SYRE's stock
Similar Companies in Healthcare
Other companies in the same sector with AI ratings